Bromodomain epigenetic protein promotes metastatic potential in melanoma cells via increased invasiveness and decreased macrophage-mediated phagocytosis

With the advent of molecular targeted therapy and immunotherapy, the 5-years survival rate of patients with metastatic melanoma has increased (Jenkins and Fisher, 2020). Despite recent treatment advances, defining novel therapeutic targets for melanoma is still an unmet medical need for patients with resistant to those targeted therapies or immunotherapy. Epigenetic regulators have emerged as therapeutic targets for cancer therapy, of which bromodomain extra-terminal (BET) family protein BRD4 is a key reader protein that recognizes acetylated lysine residues on chromatin.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research